Erythropoietin-Beta

Phase 3Small molecule

Roche

Erythropoietin-Beta is one of 180 small molecule programs targeting Hodgkins lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

179

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hodgkins LymphomaActive, not recruiting

EncephalopathyActive, not recruiting

Myelodysplastic SyndromesActive, not recruiting

Subarachnoid HemorrhageActive, not recruiting

Hodgkins LymphomaPhase 2

Active, not recruiting

EncephalopathyPhase 3

Active, not recruiting

Myelodysplastic SyndromesPhase 2

Active, not recruiting

Subarachnoid HemorrhagePhase 2

Active, not recruiting

Competition

Competitive Landscape

207 competitors in Myelodysplastic Syndromes

#DrugCompanyPhaseTrials

Reblozyl

Bristol-Myers Squibb

Phase 3

15 2

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3

8 3

Promacta

GSK

Phase 3

2 4

Thalomid

Bristol-Myers Squibb

Phase 3

2 5

Fludara

Sanofi

Phase 3

2 6

Xospata

Astellas

Phase 3

1 7

Rydapt

Novartis

Phase 3

1 8

Neupogen

EEastern Cooperative Oncology Group

Phase 3

4 9

Zarnestra

KKura Oncology, Inc.

Phase 3

4 10

Cerubidine

EEastern Cooperative Oncology Group

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

After Cardiac Surgery1 trial

Effect of Erythropoietin (EPO) in Kidney After Cardiac Surgery

Completed·SSeoul National University Bundang Hospital·Phase 2/3·NCT00654992·71 enrolled

Myelodysplastic Syndromes1 trial

A Study of NeoRecormon (Epoetin Beta), CellCept (Mycophenolate Mofetil) and Prednisone in Patients With Low or Intermediate Myelodysplastic Syndromes.

Completed· Roche logo

Roche·Phase 2·NCT00551291·10 enrolled

Hodgkins lymphoma1 trial

Feasibility and Efficacy of BACOPP-21 for Patients > 60 Years With Intermediate or Advanced Hodgkins Lymphoma

Completed·UUniversity of Cologne·Phase 2·NCT00284271·65 enrolled

Encephalopathy1 trial

Efficacy of Erythropoietin to Improve Survival and Neurological Outcome in Hypoxic Ischemic Encephalopathy

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT01732146·120 enrolled

Subarachnoid Hemorrhage1 trial

Erythropoietin Therapy for Subarachnoid Hemorrhage

Completed·UUniversity of Cambridge·Phase 2·NCT00140010·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Erythropoietin-Beta. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Erythropoietin-Beta compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Erythropoietin-Beta. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Roche

Erythropoietin-Beta

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

After Cardiac Surgery1 trial

Myelodysplastic Syndromes1 trial

Hodgkins lymphoma1 trial

Encephalopathy1 trial

Subarachnoid Hemorrhage1 trial

References

Drug Info

Quick Facts

Related News